Background Cervical cancer is a major public health problem in Latin America and the
Caribbean (LA&C), showing some of the highest incidence and mortality rates worldwide …

Abstract Background Human Papillomavirus (HPV) in cervical epithelium has been
identified as the main etiological factor in the developing of Cervical Cancer (CC), which has …

Human Papillomavirus (HPV) vaccines have been considered potentially cost‐effective for
the reduction of cervical cancer burden in developing countries; their effectiveness in a …

Data on human papillomavirus (HPV) type distribution in invasive and pre‐invasive cervical
cancer is essential to predict the future impact of HPV16/18 vaccines and HPV‐based …

Cervical cancer prevention is based on primary prevention with vaccines against Human
Papillomavirus (HPV) and secondary prevention by screening with High‐Risk‐HPV (Hr …

OBJECTIVE: Cervical cancer is an important cause of mortality among women in developing
countries, especially in the Latin America and Caribbean (LAC) region. Infection with high …

Background We estimated the potential impact of an investigational 9-valent human
papillomavirus (HPV) vaccine (HPVs 6/11/16/18/31/33/45/52/58) in HPV-related cervical …

Background Cervical cancer (CC) is the fourth most common malignancy of the female
genital tract. Human Papillomavirus (HPV) is the main cause of precancerous lesions and …

The proportion of HPV16 and 18-associated cervical cancer (CC) appears rather constant
worldwide (≥ 70%), but the relative importance of the other HR-HPV differs slightly by …

Background. Baseline information on human papillomavirus (HPV) prevalence and type
distribution is highly desirable to evaluate the impact of prophylactic HPV vaccines in the …